- Research Article
1
- 10.12788/cp.0405
Adult ADHD: A sensible approach to diagnosis and treatment
- Nov 01, 2023
- Current Psychiatry
- Samuel R Weber
A ttention-deficit/hyperactivity disorder (ADHD) is common, with an estimated worldwide prevalence of 5.29% among children and adolescents and 2.5% among adults. 1 DSM-5-TR classifies ADHD as a neurodevelop mental disorder, "a group of conditions with onset in the developmental period [that] typically manifest early in development, often before the child enters school." 2 Because of the expectation that ADHD symptoms emerge early in development, the diagnostic criteria specify that symptoms must have been present prior to age 12 to qualify as ADHD. However, recent years have shown a significant increase in the number of patients being diagnosed with ADHD for the first time in adulthood. One study found that the diagnosis of ADHD among adults in the United States doubled between 2007 and 2016. 3 First-line treatment for ADHD is the stimulants methylphenidate and amphetamine/dextroamphetamine. In the United States, these medications are classified as Schedule II controlled substances, indicating a high risk for abuse. However, just as ADHD diagnoses among adults have increased, so have prescriptions for stimulants. For example, Olfson et al 4 found that stimulant prescriptions among young adults increased by a factor of 10 between 1994 and 2009. The increased prevalence of adult patients diagnosed with ADHD and taking stimulants frequently places clinicians in a position to consider the validity of existing diagnoses and evaluate new patients with ADHD-related concerns. In this These steps can help ensure accurate diagnosis and optimal outcomes
Read more